source
- Roivant's mosliciguat shows strong efficacy in Phase 2 PH-ILD trialRoivant's experimental drug mosliciguat achieved strong efficacy signals in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The mid-stage trial met its…
- August 2026 biopharma layoffs affect just over 500 workers, a 90% drop from a year earlierIn August 2026, twelve biotech and pharmaceutical firms announced workforce reductions, impacting a total of about 526 employees. This represents a sharp 90% decline in the number of people affecte…